Table 2.

Effects of SGLT2 inhibitors on renaldysfunction.

	Empagliflozin	Canagliflozin	Dapagliflozin
Composite of renal worsening
end-stage renal disease, and renal death	Sinificantlydesirerable	Sinificantlydesirerable	Sinificantlydesirerable
Progression of macroalbuminuria	Sinificantly desirerable	Sinificantly desirerable	N.A.
new onset of microalbuminuria	Sinificantly desirerable	Sinificantly desirerable	N.A.
new onset of microalbuminuria	Sinificantly desirerable	Sinificantly desirerable	N.A.
occurrence of ESKD	Sinificantly desirerable	Sinificantly desirerable	N.A.
reduction of UACR	N.A.	Sinificantly desirerable	Sinificantly desirerable
reduction of eGFR	Sinificantlydesirerable	Sinificantlydesirerable	Sinificantly desirerable
Reference	34	35, 36	37

N.A.: not available; ESKD: endsatgekidney disease; UACR: albumin(mg)-to-creatinine (g) ratio; eGFR: estimatedglomerular filtration rate.